Chapter

Beta-blockers and chronic heart failure

Edward Duncan and Marc Goethals

in Chronic Heart Failure

Published on behalf of Oxford University Press

ISBN: 9780199542338
Published online May 2011 | e-ISBN: 9780199607174 | DOI: http://dx.doi.org/10.1093/med/9780199542338.003.0006

Series: Oxford Cardiology Library

Beta-blockers and chronic heart failure

Show Summary Details

Preview

• The combination of angiotensin-converting-enzympe inhibitors and beta-blockers is now established as the key therapy for patients with chronic heart failure (CpHF) across all functional classes. • Beta-blockers may initially worsen symptoms but their long-term effects favourably influence key pathophysiological processes leading to death and disability in patients with CHF. • Beta-blockers have favourable effects on mortality from both progressive heart failure and sudden cardiac death. • A number of beta-blockers have been shown to be effective in randomized controlled clinical trials; these agents should be the treatment of choice in patients with CHF. • Airways disease is not a contraindication to beta-blockade; the benefits in most cases may outweigh the risks. The majority of such patients should undergo a trial of therapy.

Chapter.  2195 words. 

Subjects: Cardiovascular Medicine

Full text: subscription required

How to subscribe Recommend to my Librarian

Buy this work at Oxford University Press »

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.